-
Mashup Score: 0Predicting Long-Term Effects Among Patients Treated for Early-Stage Hodgkin Lymphoma - 6 month(s) ago
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses the management and prediction of long-term effects among patients treated for early-stage Hodgkin lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Analyzing the Role of BTK Inhibitors and Combination Therapies in the Frontline Treatment of Patients With CLL - 6 month(s) ago
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, John Allan, MD, analyzes the role of BTK inhibitors and combination therapies in the frontline treatment of patients with chronic lymphocytic leukemia.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Incorporating IDH and Menin Inhibitors as Therapies for Subsets of Patients With AML - 6 month(s) ago
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amir Fathi, MD, shares insights on the emergence of IDH and menin inhibitors as therapies to target certain subsets of patients with acute myeloid leukemia.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Here, Amir Fathi, MD, shares insights into the incorporation of #IDH and #menin inhibitors as therapies for subsets of patients with acute myeloid leukemia #AML, which he presented at the 2023 #GDUHem meeting. Learn more: https://t.co/hqMryDRbTi @MGHCancerCenter @GreatDebatesCME https://t.co/prcgrbr0Rb
-
-
Mashup Score: 0Virtual - 8 month(s) ago
ON-DEMAND Q: Will I be able to watch session recordings after the meeting has concluded? A: Session replay will be available once the event concludes if you purchase an on-demand package. Q: What is included with the on-demand packages? A: When you register for the Plus or Premium Plus Package, you will have extended access to the sessions that were presented live plus additional access to…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Should ASCT be Standard of Care for Frontline Treatment of Patients With Multiple Myeloma? - 8 month(s) ago
C. Ola Landgren, MD, PhD, participated in a debate on whether melphalan plus ASCT after induction therapy should continue to be the standard of care in frontline treatment of patients with multiple myeloma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Benefits of HSCT for Patients With AML With MRD After Initial Therapy - 10 month(s) ago
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting in New York, New York, Andrew Artz, MD, participated in a debate about the benefits of hematopoietic stem cell transplantation among patients with AML with MRD after initial therapy.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Amer Zeidan, MBBS, MHS, discussed effective risk stratification among patients with myelodysplastic syndromes.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Considering MRD Before HSCT for Patients With Acute Myeloid Leukemia - 10 month(s) ago
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, Richard Stone, MD, debated the role of measurable residual disease when considering hematopoietic stem cell transplantation for patients with acute myeloid leukemia.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies #GDUHem meeting, Richard Stone, MD, discussed the role of #MRD when considering #HSCT for patients with #AML. Follow along as he shares his insights! https://t.co/tEPPqkhfge… @GreatDebatesCME @DanaFarber https://t.co/vYp7HN2MgQ
-
-
Mashup Score: 0Choosing Treatment Options for Patients With R/R DLBCL Ineligible for CAR T-Cell Therapy - 11 month(s) ago
At the 2023 Great Debates & Updates in Hematologic Malignancies in New York, New York, Jennifer Amengual, MD, discussed the process of choosing among non-CAR-T options for patients with recurrent aggressive lymphoma, particularly DLBCL.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to Jennifer Amengual, MD, "We have to think very carefully about enrolling our patients in trials as this is how we learn how to best incorporate these therapies." Follow along as Dr Amengual shares more: https://t.co/LvGH3GHV0P #GDUHem @GreatDebatesCME @ColumbiaMed https://t.co/bWcgz8fp5x
-
-
Mashup Score: 0Analyzing Patient Selection and the Utility of CNS Prophylaxis for Patients With DLBCL - 11 month(s) ago
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Here, Andrew Evens, DO, MBA, MSc, discusses the management and prediction of long-term effects among younger patients treated for early-stage Hodgkin #lymphoma at the 2023 #GDUHem meeting. Learn more: https://t.co/lsYg4stphA @DrAEvens @GreatDebatesCME @RutgersCancer #MedTwitter https://t.co/fsRpXqi6MU